Sheet 1 of 1

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
JUN 20 2008
PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.	SERIAL NO.
117-565	10/553,169
APPLICANT	
Roger R. C. NEW	
FILING DATE	**GROUP**
November 28, 2005	1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/J.H./	Chang et al, "Effect of a lipoidic excipient on the absorption profile …", J. Pharm. Pharmaceut. Sci (www.ualberta.ca/~csps) &(1):8-12, 2004.
	Atta et al, "Influence of a Niosomal Formulation on the Oral Bioavailability …", AAPS PharmSciTech 2007; 8(4) Article 106 (http://www.aapspharmscitech.org).
	Ke et al, "Enhanced Oral Bioavailability of Doxorubicin in a Dendrimer …", Journal of Pharmaceutical Sciences, Vol. 97, No. 6, June, 2008.
	Extract from the Merck index (page 480 and title page).
/J.H./	A US EPA report entitled "Alkylphenois Category (SECTION ONE)"pp. 1-41, April 19, 2006 stamped.

*Examiner	/Julie Ha/	Date Considered	07/22/2008

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial a this form with next communication to application.